SCHEMBL29696802

SCHEMBL29696802

NC(=O)C1C=Cc2ccccc2O1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.41
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 1/20 0.35
LMNA P02545 2/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
SCN4A P35499 1/20 0.34
SCN5A Q14524 1/20 0.34
SCN9A Q15858 1/20 0.34
CYP2C9 P11712 1/20 0.34
SIRT1 Q96EB6 10/20 0.34
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
SIRT2 Q8IXJ6 6/20 0.32
TRPA1 O75762 2/20 0.32
ALOX5 P09917 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4410965 1.00 ATM (0.41) ATMKDM4EALDH1A1HPGDLMNA
SCHEMBL2971408 1.00 ATM (0.41) ATMKDM4EALDH1A1HPGDLMNA
Hydrochloric Acid SCHEMBL19744196 0.98 ATM (0.40) ATMKDM4EALDH1A1HPGDLMNA
SCHEMBL7422369 0.88 ATM (0.38) ATMKDM4EALDH1A1HPGDLMNA
SCHEMBL7422383 0.88 ATM (0.38) ATMKDM4EALDH1A1HPGDLMNA
SCHEMBL29366932 0.85 KDM4E (0.40) ATMKDM4EALDH1A1HPGDTSHR
SCHEMBL990076 0.85 KDM4E (0.40) ATMKDM4EALDH1A1HPGDTSHR
SCHEMBL28806661 0.85 KDM4E (0.40) ATMKDM4EALDH1A1HPGDTSHR
Hydrochloric Acid SCHEMBL6994200 0.84 ALDH1A1 (0.39) ATMKDM4EALDH1A1HPGDTSHR
SCHEMBL1976011 0.82 ATM (0.33) ATMKDM4EALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240108608-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS THE SCHEPENS EYE RESEARCH INSTITUTE, INC. 2024-04-04 US claimed
EP-4267246-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS The Schepens Eye Research Institute, Inc. (US) 2023-11-01 EP claimed
WO-2022140551-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) 2022-06-30 WO claimed
US-12319659-B2 Selective ligand for dopamine D3 receptor, preparation method therefor, and pharmaceutical application thereof SHENZHEN LINGLAN BIO-PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) 2025-06-03 US disclosed
CN-115536644-B Application of chromone-2-formamide compound in preparation of hypoglycemic drugs and preparation method thereof 广西民族大学 2024-09-03 CN disclosed
US-20240108608-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS THE SCHEPENS EYE RESEARCH INSTITUTE, INC. 2024-04-04 US disclosed
EP-4267246-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS The Schepens Eye Research Institute, Inc. (US) 2023-11-01 EP disclosed
WO-2022140551-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) 2022-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12319659-B2 Selective ligand for dopamine D3 receptor, preparation method therefor, and pharmaceutical application thereof DRD3, DRD2, PRLHR ATM 4052/4885KDM4E 4669/4885ALDH1A1 1371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.